AEX:BTH

Breathtec Biomedical Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume101,838 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive BTH News and Ratings via Email

Sign-up to receive the latest news and ratings for Breathtec Biomedical and its competitors with MarketBeat's FREE daily newsletter.


About Breathtec Biomedical

Breathtec Biomedical, Inc., through its subsidiary, Nash Pharmaceuticals Inc., focuses on drug repurposing in the areas of non-alcoholic steatohepatitis, chronic kidney, and inflammatory bowel diseases. Its lead compound is the NP-178 for use in the treatment of ulcerative colitis. The company also develops NP-120 that is clinically used for the treatment of ulcerative colitis and Crohn's diseases. Breathtec Biomedical, Inc. is headquartered in Vancouver, Canada.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.66 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Breathtec Biomedical (AEX:BTH) Frequently Asked Questions

What stocks does MarketBeat like better than Breathtec Biomedical?

Wall Street analysts have given Breathtec Biomedical a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Breathtec Biomedical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Breathtec Biomedical's key executives?

Breathtec Biomedical's management team includes the following people:
  • Mr. Michael S. M. Sadhra CA, CPA, CFO & Director (Age 50)
  • Dr. Michael T. Costanzo Ph.D., Chief Technical Officer (Age 30)
  • Mr. Alfred Wong, VP of Corp. Devel. & Communications
  • Mr. Christopher J. Moreau, Chief Exec. Officer
  • Colin Trethewey, Exec.

Who are some of Breathtec Biomedical's key competitors?

What is Breathtec Biomedical's stock symbol?

Breathtec Biomedical trades on the AEX under the ticker symbol "BTH."

What is Breathtec Biomedical's official website?

The official website for Breathtec Biomedical is www.breathtecbiomedical.com.


This page was last updated on 7/29/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.